| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 風濕性
> 乾燥綜合症 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| For the authorisation of medicinal products for rare diseases. | 內分泌
> 腎上腺及腦垂體疾病 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 100 | National | Rarely | 119052076100 |
| We are engaged in formal consultation processes. | 內分泌
> 糖尿病（1型及2型） | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | Do not know | National | Rarely | 119035824614 |
| Advisory board of Swissmedic. | 癌症
> 癌症：肺 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | National | Sometimes | 119061399060 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 風濕性
> 乾燥綜合症 | 監管合作夥伴關係
> 與其他醫療倡導者 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | 皮膚
> 血管性水腫 | 監管合作夥伴關係
> 與其他醫療倡導者 | 100 | National | Sometimes | 119052980204 |
| Via our umbrella organisation HOPOS [Hemato-Onkologische Patientenorganisationen Schweiz - Swiss Umbrella Organisation of Haemato-Oncological Patient Organisations]. | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 與其他醫療倡導者 | 1,000 | National | Rarely | 119077844806 |
| To advocate for the establishment of an information policy directed at local authorities. | 癌症
> 癌症：前列腺 | 影響政策及立法
> 影響醫療保健政策及立法 | 100 | Regional | Sometimes | 115056429435 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. | 風濕性
> 乾燥綜合症 | 影響政策及立法
> 影響醫療保健政策及立法 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| Legislative adaptation through ongoing communication. | 罕見
> 罕見疾病：兒童／青少年 | 影響政策及立法
> 影響醫療保健政策及立法 | 1,000 | National | Sometimes | 119035891744 |
| Consultation on legislative drafts, and specific requests for assistance — whether material, structural, or socio-economic in nature. | 病人教育
> 病人教育 | 影響政策及立法
> 影響醫療保健政策及立法 | 100 | National | Sometimes | 119035955624 |
| The Swiss Cancer Plan, in collaboration with Oncosuisse and the BAG [Bundesamt für Gesundheit – Federal Office of Public Health]. | 癌症
> 癌症：前列腺 | 影響政策及立法
> 影響醫療保健政策及立法 | 1,000 | National | Regularly | 119044110604 |
| Advocacy representation in relation to the new care legislation. | 神經退行性
> 阿茲海默症 | 影響政策及立法
> 影響醫療保健政策及立法 | 100,000 | National | Regularly | 119044141359 |
| Consultation on legislative drafts, and specific requests for assistance — whether material, structural, or socio-economic in nature. | 病人教育
> 病人教育 | 影響政策及立法
> 參與起草公共衛生法規 | 100 | National | Sometimes | 119035955624 |
| Advocacy representation in relation to the new care legislation. | 神經退行性
> 阿茲海默症 | 影響政策及立法
> 參與起草公共衛生法規 | 100,000 | National | Regularly | 119044141359 |
| Support with formal cost-approval (reimbursement authorisation) applications and with newly introduced restrictions on treatment options. | 心血管
> 家族性高膽固醇血症（FH） | 影響政策及立法
> 處理醫療護理中的障礙/異常情況 | 100 | National | Sometimes | 119072887138 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 風濕性
> 乾燥綜合症 | 定價及可負擔性倡議
> 倡導公平藥品定價 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| We work to ensure that effective medicines are available to patients in a fair and timely way, and we explain how pricing and reimbursement decisions directly affect patients and their families in real life. | 癌症
> 癌症：肺 | 定價及可負擔性倡議
> 倡導公平藥品定價 | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| Support with reimbursement approvals. | 心血管
> 家族性高膽固醇血症（FH） | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100 | National | Sometimes | 119072887138 |
| Primarily through public appeals, media coverage, and similar channels [on issues of drug pricing]. | HIV
> HIV | 定價及可負擔性倡議
> 參與宣傳活動 | 5,000 | National | Rarely | 119035314201 |
| Assisting a family in accessing a medication covered by their insurance. | 神經系統
> 神經纖維瘤病（NF） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100 | Regional | Rarely | 115023088362 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | 皮膚
> 血管性水腫 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100 | National | Sometimes | 119052980204 |
| We work to ensure that effective medicines are available to patients in a fair and timely way, and we explain how pricing and reimbursement decisions directly affect patients and their families in real life. | 癌症
> 癌症：肺 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 風濕性
> 乾燥綜合症 | 改善存取途徑
> 改善罕見/極罕見療法的獲取途徑 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| For the authorisation of medicinal products for rare diseases. | 內分泌
> 腎上腺及腦垂體疾病 | 改善存取途徑
> 改善罕見/極罕見療法的獲取途徑 | 100 | National | Rarely | 119052076100 |
| ... Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 風濕性
> 乾燥綜合症 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| We speak up to make sure patients' views are properly taken into account when decisions are made about access to new treatments, their cost, and their value. | 癌症
> 癌症：肺 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| We speak up to make sure patients' views are properly taken into account when decisions are made about access to new treatments, their cost, and their value. | 癌症
> 癌症：肺 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | 皮膚
> 血管性水腫 | 以實證為基礎的患者意見
> 將證據與洞見轉化為政策建議 | 100 | National | Sometimes | 119052980204 |
| Participation in the RDA [Research Data Alliance]-Forum / CTA [Clinical Trial Authorisation] activities. | 風濕性
> 硬皮病 | 診斷及藥物送遞
> 協作設計臨床試驗 | 100 | National | Rarely | 119056569513 |
| Through physicians, hospitals, and participation in PPI [Patient and Public Involvement] meetings. | 癌症
> 癌症：兒童／青少年 | 機構管治
> 在多方持份者網絡中有效運作 | 100 | National | Sometimes | 115032067078 |
| The Swiss Cancer Plan, in collaboration with Oncosuisse and the BAG [Bundesamt für Gesundheit – Federal Office of Public Health]. | 癌症
> 癌症：前列腺 | 機構管治
> 在多方持份者網絡中有效運作 | 1,000 | National | Regularly | 119044110604 |
| We are a non-profit (ZEWO [Zentralstelle für Wohlfahrtsunternehmen - Central Office for Welfare Organisations]-certified) organisation. | 心理健康
> 抑鬱症 | 機構管治
> 維持公益或慈善機構的正式地位 | 1,000 | Regional | No | 119063159875 |
| Support for obtaining AI [Assurance Invalidité – Disability Insurance]. | 視覺障礙
> 視覺障礙 | 維護病人權益／提升生活質素
> 保護/改善患者體驗 | 100 | Regional | Sometimes | 114996630534 |
互動
行動與倡議
7 提及
